Cavitation Technologies Inc. (OTC:CVAT) Stock In Focus After Major Update
Considering the fact that Cavitation Technologies Inc. (OTC: CVAT) had been in sharp focus yesterday following a key announcement, it could be a good time to take a closer look into it this morning.
Cavitation Technologies, Inc. and Desmet Belgium S.A. Sign Agreement That Will Allow CTi to Monetize Parts of Its IP Portfolio While Retaining Worldwide Exclusive Licenses in Its Primary Business Lines
The company announced yesterday that it had gone into an agreement with Desmet Belgium SA. The company stated that once the transaction was completed between the two parties, Desmet would work on the monetization of some of the United States and non-United States patents of the company and associated intellectual property. It should be noted that the assets had been licensed to Desmet for worldwide use in fats, vegetable oils, and applications for many years.
Agreement Details
As per the provisions of the agreement, Cavitation Technologies would transfer and assign a number of United States and non-United States patents to Desmet. It would also transfer any associated information with regards to those patents, which are already licensed to Desmet.
Thanks to the agreement, the company would also reserve for itself and receive a license back. The license would be exclusive, worldwide, non-transferable, and royalty-based. The agreement would allow the company to not only monetize its patents already licensed to Desmet but also retain the exclusive rights and licenses that it would need to help in building further business relationships.
CEO Quote
“Once completed, this transaction will enable the company to monetize the value of the IP rights already under license to Desmet, while at the same time retaining a full range of exclusive licenses and rights required by the company to continue the development of business partnerships, projects, and opportunities in our primary lines of business. It will also generate substantial capital for the company, providing support for our current business plans without any dilution of our shareholders.”
Technicals
| +/- EMA(20) | 0.0093 (+7.53%) |
| +/- SMA(50) | 0.0083 (+20.48%) |
| +/- SMA(200) | 0.0119 (-15.97%) |
| 5-Day Perf. | +14.94% |
| 1-Month Perf. | +20.48% |
| 3-Month Perf. | -13.79% |
| 6-Month Perf. | -28.57% |
| YTD Perf. | -38.65% |
| 1-Year Perf. | -25.93% |
| RSI(14) | 58.06 |
| ATR(14) | – |
| ADX(14) | 17.82 |
